Johnson & Johnson stops mid-stage trial of drug for dengue prevention
Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.
Drugs
Health
Pharma
Drugs
Health
Pharma
J&J to build $2b facility in North Carolina to make future products
HQ Team October 2, 2024: Johnson & Johnson will invest $2 billion to build a biologics manufacturing facility in Wilson, North Carolina, anticipating.
Drugs
Health
Pharma
J&J plans to acquire Israel’s V-Wave by paying $600 million upfront
Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the.
Drugs
Health
Pharma
Johnson & Johnson to buy Proteologix Inc., for $850 million in cash
HQ Team May 17, 2024: Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to.
Drugs
Health
Pharma
Johnson & Johnson’s blood cancer medicine cleared for bi-weekly use
HQ Team February 21, 2024: Johnson & Johnson announced that USFDA had approved a bi-weekly dose of its blood cancer therapy Tecvayli. The regulatory.
Drugs
Health
Pharma
FDA probing T cell cancer therapies of Gilead Sciences, Novartis, J & J
HQ Team November 29, 2023: The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies.
Health
Medical
Pharma
J&J to file USFDA request to start trials for surgical robots
Johnson & Johnson will apply with the USFDA to start clinical trials in the second half of 2024 for its robotic surgical system.
Drugs
Health
Pharma
GSK to pay $1 billion to acquire exclusive rights for J&J hepatitis B therapy
HQ Team November 1, 2023: GSK, a British pharmaceutical company, will pay $1 billion to Johnson & Johnson for transferring exclusive global rights.
Drugs
Health
Pharma
J&J halts final phase of trials of a drug to treat hypertension, says “futile”
HQ Team September 7, 2023: Johnson & Johnson has decided to halt an experimental trial, in its final stages, on a drug to.
Drugs
Pharma
Johnson & Johnson pulls out of HIV phase III trial
Johnson & Johnson stopped the phase III trial of its global HIV vaccine trial after it found that the regimen was ineffective in.